Hematology

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with lisocabtagene maraleucel experienced durable responses.

The antifungal prophylaxis azoles did not impact the safety and efficacy of ruxolitinib in patients with graft-vs-host disease.

Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.

Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.

After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.

Blinatumomab tended to be safe and effective in the treatment of children or young adults with B-cell acute lymphoblastic leukemia, potentially offering a treatment regimen less toxic than chemotherapy.

The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.

High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.

At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

"Differential diagnoses in patients with bicytopenia—particularly those with preserved platelets—are broad and require careful physical examination."

Brexucabtagene autoleucel was associated with a 91% overall response rate among patients with relapsed/refractory mantle cell lymphoma.

During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.

Acalabrutinib, whether as monotherapy or as part of a combination, demonstrated superior progression-free survival outcomes compared to obinutuzumab and chlorambucil.

Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.

The overall response rate with ibrutinib plus venetoclax was 82% vs 74% with ibrutinib plus placebo.

The 4-year progression-free survival rate with daratumumab, bortezomib, lenalidomide, and dexamethasone was 84.3% vs 67.7% with just bortezomib, lenalidomide, and dexamethasone.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation lowered relapse and progression rates in relapsed large B-cell lymphoma.

The rate of minimal residual disease negativity at 21 months was 77% among patients who received isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone.

A new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.

Overall, 65.9% of patients who received the combination of pelabresib and ruxolitinib demonstrated a 35% or greater reduction in spleen volume by week 24.